School of Medicine, Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel.
School of Medicine, Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel; Sieratzki-Sagol Institute for Sleep Medicine, Tel Aviv Sourasky Medical Center, Israel.
J Psychiatr Res. 2024 Jul;175:211-217. doi: 10.1016/j.jpsychires.2024.05.033. Epub 2024 May 9.
The relation between impulsivity and sleep indices is not well determined in patients receiving methadone maintenance treatment (MMT).
to evaluate high impulsivity prevalence, its risk factors and relation with sleep indices.
a random MMT sample (n = 61) plus MMT current cocaine users (n = 20) were assessed for impulsivity (Barratt impulsivity scale [BIS-11] and Balloon Analogue Risk task [BART]), sleep quality (Pittsburg Sleep Quality Index [PSQI]), sleepiness (The Epworth sleepiness scale [ESS]), and substance in urine.
81 patients, aged 56.6 ± 10, 54.3% tested positive to any substance, 53.1% with poor sleep (PSQI>5) and 43.2% with daytime sleepiness (ESS >7) were studied. Impulsivity (BIS-11 ≥ 72) prevalence was 27.9% (of the representative sample), and 30.9% of all participants. These patients characterized with any substance and shorter duration in MMT with no sleep indices or other differences including BART balloon task performance (that was higher only in any substance than non-substance user group). However, impulsive score linearly correlated with daytime sleepiness (R = 0.2, p = 0.05). Impulsivity proportion was lowest among those with no cocaine followed by cocaine use and the highest in those who used cocaine and opiates (20.8%, 33.3% and 60% respectively, p = 0.02), as daily sleep (38.3%, 42.1% and 60%, p = 0.3) although not statistically significant.
Daytime sleepiness correlated with impulsivity, but cocaine usage is the robust factor. Further follow-up is warranted to determine whether substance discontinuing will lead to a reduction in impulsivity, and improved vigilance. Sleep quality did not relate to daytime sleepiness and impulsivity and need further research.
接受美沙酮维持治疗(MMT)的患者,冲动性与睡眠指数之间的关系尚不清楚。
评估高冲动性的患病率、其危险因素及其与睡眠指数的关系。
对随机 MMT 样本(n=61)和 MMT 目前可卡因使用者(n=20)进行冲动性评估(Barratt 冲动性量表[BIS-11]和气球模拟风险任务[BART])、睡眠质量(匹兹堡睡眠质量指数[PSQI])、嗜睡(Epworth 嗜睡量表[ESS])和尿液中的物质。
共研究了 81 名年龄为 56.6±10 岁的患者,54.3%的患者检测出任何物质呈阳性,53.1%的患者睡眠质量差(PSQI>5),43.2%的患者白天嗜睡(ESS>7)。冲动性(BIS-11≥72)的患病率为 27.9%(代表性样本)和 30.9%的所有参与者。这些患者的特点是有任何物质,MMT 持续时间较短,没有睡眠指数或其他差异,包括 BART 气球任务表现(仅在有物质的情况下高于无物质使用者组)。然而,冲动性评分与白天嗜睡呈线性相关(R=0.2,p=0.05)。在没有可卡因的情况下,冲动性比例最低,其次是可卡因使用者,最高的是可卡因和阿片类药物使用者(分别为 20.8%、33.3%和 60%,p=0.02),尽管这并不具有统计学意义,但每日睡眠时间分别为 38.3%、42.1%和 60%。
白天嗜睡与冲动性相关,但可卡因使用是一个强有力的因素。需要进一步随访以确定是否停止使用物质会导致冲动性降低和警觉性提高。睡眠质量与白天嗜睡和冲动性无关,需要进一步研究。